Clément Couteaux

Mr. Clément Couteaux


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Emerging Infectious Diseases
Verified
Journal Article
Open access
CCClément Couteaux
Clément Couteaux
TDThibaut Demaneuf
Thibaut Demaneuf
LBLaurent Bien
Laurent Bien
MMManuel Munoz
Manuel Munoz
BWBernadette Worms
Bernadette Worms
CGCyrille Goarant
Cyrille Goarant
Lymphatic Filariasis, Futuna, 2024

Verified
Journal Article
Open access
PDF file
Adam T CraigAdam T Craig
Adam T Craig
Harriet LawfordHarriet Lawford
Harriet Lawford
TBTemea Bauro
Temea Bauro
CCClément Couteaux
Clément Couteaux
LVLitiana Volavala
Litiana Volavala
Colleen LauColleen Lau
Colleen Lau
Lymphatic filariasis (LF) is a mosquito-borne neglected tropical disease targeted by the World Health Organization (WHO) for global elimination as a public health problem. Sixteen Pacific Island countries and territories were historically endemic, and eight have now met the WHO criteria for elimination as a public health problem. Elimination as a public health problem does not imply zero transmission. Rather, it denotes that LF prevalence has been reduced below a defined threshold at which community transmission can be sustained. Following validation of elimination, the WHO recommends post-validation surveillance (PVS) to detect potential re-emergence of LF as a public health problem. However, implementing PVS is challenging in Small Island Developing States with dispersed populations, limited workforce capacity, resource constraints, and competing health priorities. The ‘Voices and Visions: Building Partnerships for Integrated Serosurveillance of LF and Other Infectious Diseases in the Pacific Islands’ meeting was held in Brisbane, Australia, from 8–10 July 2025. Fifty-one delegates, including Pacific LF programme managers, WHO representatives, global health partners, and academic researchers, reviewed regional PVS progress, discussed the newly released WHO guidelines for the implementation, monitoring, and evaluation of PVS, planned for PVS implementation, and explored novel multiplex bead assay (MBA) serological analysis methods to strengthen regional coordination for its development as a public health tool. Five broad themes emerged. First, the new WHO Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes, 2nd edn needs to be operationalised to meet decision-making needs across diverse Pacific settings. Second, integrating LF-PVS with existing surveys and health service activities could improve efficiency and long-term sustainability. Third, regional coordination and alignment of funding cycles will require high-level collaboration. Fourth, community engagement is essential to strengthen demand for PVS. Finally, while at an early stage and with further evidence needed, MBA laboratory methods hold promise for cost-effective, feasible integrated multi-pathogen serosurveillance.

Verified
Journal Article
Open access
PDF file
Adam T CraigAdam T Craig
Adam T Craig
CCClément Couteaux
Clément Couteaux
KJKen Jetton
Ken Jetton
RNRoger Nehemia
Roger Nehemia
OSOliver Sokana
Oliver Sokana
Harriet LawfordHarriet Lawford
Harriet Lawford
Lymphatic filariasis (LF) is a mosquito-borne neglected tropical disease that causes substantial morbidity and social exclusion. Global efforts under the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis have markedly reduced prevalence, and several Pacific Island Countries and Territories (PICTs) have achieved elimination of the disease as a public health problem. However, post-validation surveillance (PVS), essential for detecting resurgence and enabling early response, has rarely been implemented, and barriers to its delivery remain poorly understood. We used two complementary qualitative approaches to identify systemic barriers and enablers to LF PVS in PICTs. First, we conducted a Nominal Group Technique followed by a structured expert elicitation involving program managers and technical staff. Data were analysed thematically and triangulated across sources. Participants identified 70 challenges which were consolidated into ten thematic domains. Pertinent barriers relate to limited leadership understanding of LF and surveillance options, inconsistent technical and financial support, and a lack of context-appropriate operational guidance. Additional challenges included limited field-ready diagnostics, procurement delays, the absence of formal mandates, and low community engagement. Enablers included embedding PVS within existing health services, leveraging trusted community networks, strengthening regional frameworks, and co-developing practical tools with countries. Sustaining LF elimination in the Pacific will require political commitment, regional collaboration, and integrated, programmatic approaches informed by recent PVS experience.

Verified
Journal Article
Open access
PDF file
Harriet LawfordHarriet Lawford
Harriet Lawford
HJHolly Jian
Holly Jian
‘T‘Ofa Tukia
‘Ofa Tukia
JTJoseph Falealea A Masila Takai
Joseph Falealea A Masila Takai
CCClément Couteaux
Clément Couteaux
Adam T CraigAdam T Craig
Adam T Craig
Eight Pacific Island Countries and Territories (PICTs) have been validated by the World Health Organization (WHO) as having eliminated lymphatic filariasis (LF) as a public health problem. WHO recommends that these countries implement post-validation surveillance (PVS) to ensure resurgence has not occurred. Some PICTs proactively conducted LF PVS even in the absence of specific recommendations or best-practice guidelines at the time of implementation. We aimed to explore the barriers and facilitators to implementing LF PVS in PICTs, with a view to informing context-specific strategies and regional guidelines. Key informant interviews were held between March and September 2024 with 15 participants involved in LF and/or neglected tropical disease surveillance. Transcripts were analysed thematically using a generalised deductive approach. A conceptual framework was developed to summarise themes with two main streams of barriers identified. Stream One Barriers included limited awareness of, and guidelines for, PVS requirements and competing national health priorities. Stream Two Barriers included cost, resource, and logistical barriers to conducting PVS. Participants called for clearer, contextually tailored guidelines, improved communication from WHO, and integration within existing systems. This study highlights the urgent need for operational guidance, policy advocacy, and capacity strengthening to ensure sustainable LF PVS in PICTs. Incorporating local context and leveraging existing health structures will be essential to prevent disease resurgence and maintain gains achieved through elimination programmes.

12 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Adam T CraigAdam T Craig
Adam T Craig
CCClément Couteaux
Clément Couteaux
KJKen Jetton
Ken Jetton
RNRoger Nehemia
Roger Nehemia
OSOliver Sokano
Oliver Sokano
Harriet LawfordHarriet Lawford
Harriet Lawford
Lymphatic filariasis (LF) is a mosquito-borne neglected tropical disease that causes substantial morbidity and social exclusion. Global efforts under the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis have markedly reduced prevalence, and several Pacific Island Countries and Territories (PICTs) have achieved elimination as a public health problem. However, post-validation surveillance (PVS), essential for detecting resurgence and enabling early response, has rarely been implemented, and barriers to its delivery remain poorly understood. We used two complementary qualitative approaches to identify systemic barriers and enablers to LF PVS in PICTs. First, we conducted a Nominal Group Technique followed by a structured expert elicitation involving program managers and technical staff. Data were analysed thematically and triangulated across sources. Participants identified 70 challenges which were consolidated into ten thematic domains. Pertinent barriers relate to limited leadership understanding of LF and surveillance options, inconsistent technical and financial support, and a lack of context-appropriate operational guidance. Additional challenges included limited field-ready diagnostics, procurement delays, the absence of formal mandates, and low community engagement. Enablers included embedding PVS within existing health services, leveraging trusted community networks, strengthening regional frameworks, and co-developing practical tools with countries. Sustaining LF elimination in the Pacific will require political commitment, regional collaboration, and integrated, programmatic approaches informed by recent PVS experience.